1187836-86-7 Usage
Description
(2-Bromo-5-methylthiazol-4-yl)methanol, also known as BMTH, is a chemical compound belonging to the class of thiazole derivatives. It is recognized for its antimicrobial properties and potential therapeutic applications, making it a compound of interest to the scientific community.
Uses
Used in Pharmaceutical Synthesis:
(2-Bromo-5-methylthiazol-4-yl)methanol is used as an intermediate in the synthesis of pharmaceutical compounds, contributing to the development of new drugs.
Used in Organic Chemistry:
BMTH serves as a building block in organic chemistry, facilitating the creation of various chemical structures and compounds.
Used in Antimicrobial Agents:
(2-Bromo-5-methylthiazol-4-yl)methanol is used as a key component in the development of new antimicrobial agents, leveraging its inherent antimicrobial properties to combat infections.
Used in Disease Treatment Research:
BMTH is studied for its potential applications in the treatment of various diseases, including cancer and bacterial infections, due to its diverse pharmacological activities and therapeutic potential.
Check Digit Verification of cas no
The CAS Registry Mumber 1187836-86-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,7,8,3 and 6 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1187836-86:
(9*1)+(8*1)+(7*8)+(6*7)+(5*8)+(4*3)+(3*6)+(2*8)+(1*6)=207
207 % 10 = 7
So 1187836-86-7 is a valid CAS Registry Number.
1187836-86-7Relevant articles and documents
NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS
-
Page/Page column 90, (2021/07/31)
Provided are compounds of formula (I), or pharmaceutically acceptable salts thereof, which can be used for inhibiting the activity of Aurora A and treating cancer mediated by Aurora A.
BISARYL HETEROCYCLES AS NRF2 ACTI
-
Page/Page column 141; 142, (2018/07/05)
The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula (I),
IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
-
Paragraph 00200, (2013/11/18)
The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W,Y, R0, R2, R4, Ra, Rb, X1, X2, X3 and X4 are as defined herein,, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
